Berlin-based Booster Therapeutics receives $15M seed funding to develop novel proteasome activator medicines for Parkinson's and Alzheimer's diseases.

Booster Therapeutics, a new biotech company based in Berlin, has launched with $15 million in seed funding from Apollo Health Ventures and Novo Holdings. The company aims to develop a novel class of proteasome activator medicines to address neurodegenerative diseases, particularly Parkinson's and Alzheimer's. Unlike traditional methods, Booster's approach directly activates 20S proteasomes to degrade harmful proteins, creating a multi-disease pipeline targeting various proteinopathies.

October 10, 2024
8 Articles

Further Reading